Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has provided an update.
Biocytogen Pharmaceuticals has announced plans to issue A Shares and list them on the Sci-Tech Board, with the approval process completed by the Shanghai Stock Exchange and CSRC. The proceeds from this issuance will be used to fund various projects, including drug development and evaluation, and to supplement working capital. Additionally, the company plans to amend its Articles and abolish its Supervisory Committee in alignment with the new share issuance.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. is a pharmaceutical company based in China, primarily focused on drug development and evaluation services. The company operates in the biotech industry and aims to enhance its market presence through innovative drug development projects.
Average Trading Volume: 446,956
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.11B
Learn more about 2315 stock on TipRanks’ Stock Analysis page.